Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs

Journal of Pharmaceutical Sciences

Volumn 87, Issue 4, 1998, Pages 411-424

  Wasan, Kishor M ^a   Cassidy, Shawn M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANNAMYCIN; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL ESTER TRANSFER PROTEIN; CHYLOMICRON; CYCLOSPORIN; DRUG CARRIER; HALOFANTRINE; HIGH DENSITY LIPOPROTEIN; IMIPRAMINE; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOSOME; LOW DENSITY LIPOPROTEIN; NORTRIPTYLINE; PLASMA PROTEIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG UPTAKE; DYSLIPIDEMIA; HUMAN; HYDROPHOBICITY; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; REVIEW; SPECIES DIFFERENCE;

EID: 0031901271     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js970407a     Document Type: Article

References (126)

1. Davis, R. A.; Vance, J. E. Structure, assembly and secretion of lipoproteins. In Biochemistry of lipids, lipoproteins and membranes; Vance, D. E., Vance, J. E., Eds.; Elsevier: New York, 1996; pp 473-493.
2. Harmony, J. A. K.; Aleson, A. L.; McCarthy, B. M. Lipoprotein structure. In Biochemistry and biology of plasma lipoproteins; Scanu, A. M., Spector, A. A., Eds.; Marcel Dekker Inc: New York, 1986; pp 403-430.
3. Mbewu, A.; Durrington, P. N. Lipoprotein (a): Structure, properties, and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990, 85, 1-14.
4. Durrington, P. N. Lipoprotein assembly. In Lipoproteins and lipids; Durrington, P. N., Ed.; Wright: London, 1989; pp 255-277.
5. Davis, R. A. Lipoprotein structure and secretion. In Biochemistry of lipids, lipoproteins and membranes; Vance, D. E., Vance, J. E., Eds.; Elsevier: New York, 1991; pp 403-426.
6. Havel, R. J.; Kane, J. P. Introduction: Structure and metabolism of plasma lipoproteins. In The metabolic and molecular basis of inherited disease, Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D. (Eds.); McGraw-Hill Inc.: New York, 1995;Vol. 2, pp 1129-1138.
7. Fielding, P. E.; Fielding, C. J. Dynamics of lipoprotein transport in the human circulatory system. In Biochemistry of lipids, lipoproteins and membranes; Vance, D. E., Vance, J. E., Eds.; Elsevier: New York, 1996; pp 495-516.
8. Segrest, J. P.; Jackson, R. L.; Morrisett, J. D.; Gotto, A. M., Jr. A molecular theory of lipid-protein interactions in the plasma lipoproteins. FEBS Lett. 1974, 38, 247-258.
9. Gotto, A. M., Jr.; Pownall, H. R.; Havel, R. J. Introduction to the plasma lipoproteins. Methods Enzymol. 1986, 128, 3-41.
10. Eisenberg, S. High-density lipoprotein metabolism. J. Lipid Res. 1984, 25, 1017-1058.
11. Eisenberg, S.; Bilheimer, D. W.; Levy, R. I. The metabolism of very low-density lipoproteins. II. Studies on the transfer of apoproteins between plasma lipoproteins. Biochim. Biophys. Acta 1972, 280, 94-104.
12. Yang, C.-Y.; Chen, S.-H.; Gianturco, S. H.; Bradley, W. A.; Sparrow, J. T.; Tanimura, M.; Li, W.-H.; Sparrow, D. A.; DeLoof, H.; Rosseneu, M.; Lee, F.-S.; Gu, Z.-W.; Gotto, A. M., Jr.; Chan, L. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. Nature 1986, 323, 738-742.
13. Yang, C.-Y.; Gu, Z.-W.; Weng, S.-A.; Kim, T. W.; Chen, S.-H.; Pownall, H. J.; Sharp, P. M.; Liu, S.-W.; Li, W.-H.; Gotto, A. M. Jr.; Chan, L. Structure of apolipoprotein B-100 of human low-density lipoproteins. Arteriosclerosis 1989, 9, 96-108.
14. Chen, G. C.; Hardman, D. A.; Hamilton, R. L.; Mendel, C. M.; Schilling, J. W.; Zhu, S.; Lau, K.; Wong, J. S.; Kane, J. P. Distribution of lipid-binding regions in human apolipoprotein B-100. Biochemistry 1989, 28, 2477-2484.
15. Cladaras, C.; Hadzopoulou-Cladaras, M.; Nolte, R. T.; Atkinson, D.; Zannis, V. I. The complete sequence and structural analysis of human apolipoprotein B-100: Relationship between apoB-100 and apoB-48 forms. EMBO J. 1986, 5, 3495-3505.
16. Segrest, J. P.; Jones, V. K.; Mishra, M. K.; Anantharamaiah, G. M.; Garber, D. W. ApoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE. Arteriosclerosis Thromb. 1994, 14, 1674-1685.
17. Kane, J. P. Apolipoprotein B: Structural and metabolic heterogeneity. Annu. Rev. Physiol. 1983, 45, 205-248.
18. Chan, L. Apolipoprotein B, the major protein component of triglyceride-rich and low-density lipoproteins. J. Biol. Chem. 1992, 267, 25621-25624.
19. Wu, A.-L.; Windmueller, H. G. Variant forms of plasma apolipoprotein B. J. Biol. Chem. 1981, 256, 3615-3618.
20. Myant, N. B. Cholesterol metabolism, LDL, and the LDL receptor. Academic Press: Toronto, 1990; pp 400-430.
21. Schneider, W. J. 1996 Removal of lipoproteins from plasma. In Biochemistry of lipids, lipoproteins, and membranes. Vance, D. E., Vance, J. E., Eds.; Elsevier: New York, 1996; pp 517-541.
22. Goldstein, J. L.; Brown, M. S.; Anderson, R. G. W.; Russell, D. W.; Schneider, W. J. Receptor-mediated endocytosis: Concepts emerging from the LDL receptor system. Annu. Rev. Cell Biol. 1985, 1, 1-39.
23. Brown, M. S.; Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232, 34-47.
24. Schneider, W. J. The low-density lipoprotein receptor. Biochim. Biophys. Acta 1989, 988, 303-317.
25. Goldstein, J. L.; Brown, M. S. The low-density lipoprotein receptor pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 1977, 46, 897-930.
26. Fielding, C. J.; Fielding, P. E. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 1995, 36, 211-228.
27. Wasan, K. M.; Lopez-Berestein, G. Characteristics of lipid-based formulations that influence their biological behavior within the plasma of patients. Clin. Infect. Dis. 1996, 23, 1126-1138.
28. Kuster, G. M.; Drexel, H.; Bleisch, J. A.; Rentsch, K.; Pei, P.; Binswanger, U.; Amann, F. W. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994, 57, 1479-1483.
29. McIntosh, M. P.; Porter, C. J. H.; Wasan, K. M.; Ramaswamy, M.; Charman, W. N. The degree of association of halofantrine with pre- and post-prandial plasma lipoproteins is determined by their apolar lipid content. Pharm. Res. 1997, 14 (11), S-277.
30. Rowland, M. Plasma protein binding and therapeutic monitoring. Ther. Drug Monitor. 1980, 2, 29-37.
31. Zini, R.; Riant, P.; Barre, J.; Tillement, J. P. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (parts 1 and 2). Clin. Pharmacokinet. 1986, 19, 147-159.
32. Bickel, M. H. Binding of chlorpromazine and imipramine to red cells, albumin, lipoproteins and other blood components. J. Pharm. Pharmacol. 1975, 27, 733-738.
33. Shireman, R. B.; Remsen, J. F. Imipramine associations with plasma components and its uptake by cultured human cells. Life Sci. 1983, 33, 2165-2171.
34. Danon, A.; Chen, Z. Binding of imipramine to plasma proteins: Effect of hyperlipoproteinemia. Clin. Pharm. Ther. 1979, 25, 316-321.
35. Brinkschulte, M.; Breyer-Pfaff, U. The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn-Schmiedebergs Arch. Pharm. 1980, 314, 61-66.
36. Pike, E.; Skuterud, B.; Kierulf, P.; Lunde, P. K. Significance of lipoproteins in serum binding variations of amitriptyline, nortriptyline, and quinidine. Clin. Pharm. Ther. 1982, 32, 599-606.
37. Traber, M. G.; Packer, L. Vitamin E: Beyond antioxidant function. Am. J. Clin. Nutr. 1995, 62, 1501S-1509S.
38. Aten, R. F.; Kolodecik, T. R.; Behrman, H. R. Ovarian vitamin E accumulation: Evidence for a role of lipoproteins. Endocrinology 1994, 135, 533-539.
39. Traber, M. G. Determinants of plasma vitamin E concentrations. Free Radical Bio. Med. 1994, 16, 229-239.
40. Traber, M. G.; Sokol, R. J.; Burton, G. W.; Ingold, K. U.; Papas, A. M.; Huffaker, J. E.; Kayden, H. J. Impaired ability of patients with familial isolated vitamin E deficiency to incorporate alpha-tocopherol into lipoproteins secreted by the liver. J. Clin. Invest. 1990, 85, 397-407.
41. Gurusinghe, A.; de Niese, M.; Renaud, J. F.; Austin, L. The binding of lipoproteins to human muscle cells: binding and uptake of LDL, HDL, and alpha-tocopherol. Muscle Nerve 1988, 11, 1231-1239.
42. Vuilleumier, J. P.; Keller, H. E.; Gysel, D.; Hunziker, F. Clinical chemical methods for the routine assessment of the vitamin status in human populations. Part I: The fat-soluble vitamins A and E, and beta-carotene. Int. J. Vitamin Nutr. Res. 1983, 53, 265-272.
43. Rajaram, O. V.; Fatterpaker, P.; Sreenivasan, A. Involvement of binding lipoproteins in the absorption and transport of alpha-tocopherol in the rat. Biochem. J. 1974, 140, 509-516.
44. Ho Ngoc-Ta, T. A.; Sirois, G. Quinidine and propranolol binding to very low and low-density lipoproteins of human plasma. Can. J. Phys. Pharmcol. 1984, 62, 589-595.
45. Ho Ngoc-Ta, T. A.; Sirois, G. Competitive binding of quinidine, propranolol, and 4-OH-propranolol to human plasma very low-density (VLDL) and low-density (LDL) lipoproteins. Pharm. Acta Helv. 1985, 60, 106-109.
46. Urien, S.; Albengres, E.; Comte, A.; Kiechel, J. R.; Tillement, J. P. Plasma protein binding and erythrocyte partitioning of nicardipine in vitro. J. Cardiovascular Pharmcol. 1985, 7, 891-898.
47. Oravcova, J.; Sojkova, D.; Fetkovska, N.; Trnovec, T. Factors influencing isradipine and amlodipine binding to human plasma lipoproteins. Blood Pressure 1994, 1, Supplement, 61-64.
48. Linden, T.; Camejo, G.; Wiklund, O.; Warnold, I.; Olofsson, S. O.; Bondjers, G. Effect of short-term beta blockade on serum lipid levels and on the interaction of LDL with human arterial proteoglycans. J. Clin. Pharmacol. 1990, 30, S124-S131.
49. Seifert, T., Zschornig, O., Arnhold, J. and Arnold, K. Beta-blockers inhibit the modification of low-density lipoproteins by sodium hypochlorite in vitro. Chem. Phys. Lipids 1997, 85, 13-21.
50. Northcote, R. J.; Todd, I. C.; Ballantyne, D. Beta blockers and lipoproteins: A review of current knowledge. Scottish Med. J. 1986, 31, 220-228.
51. Wasan, K. M. Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. J. Pharmacol. Toxicol. Methods 1996, 36, 1-11.
52. Wasan, K. M.; Lopez-Berestein, G. Diversity of lipid-based polyene formulations and their behavior in biological systems. Eur. J. Clin. Microbiol. Infect. Dis. 1997, 16, 81-92.
53. Brajtburg, J.; Elberg, S.; Bolard, J.; Medoff. G. Interaction of plasma proteins and lipoproteins with amphotericin B. J. Infect. Dis. 1984, 149, 986-992.
54. Lopez-Berestein, G. Liposomes as carriers of antifungal drugs. Ann. N.Y. Acad. Sci. 1988, 544, 590-597.
55. Pontain, D. R.; Sun, D.; Brim, J. D.; et al. Inhibition of HIV replication by liposomal-amphotericin B. Antiviral Res. 1989, 13, 119-125.
56. Chabot, G. G.; Pazdur, R.; Valeriote. F. A.; Baker, L. H. Pharmacokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J. Pharm. Sci. 1989, 78, 307-310.
57. Wasan, K. M.; Conklin, J. S. Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin. Infect. Dis. 1997, 24, 78-80.
58. Wasan, K. M.; Vadiei, K.; Lopez-Berestein, G.,; Luke, D. R. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B. J. Infect. Dis. 1990, 161, 562-566.
59. Wasan, K. M.; Conklin, J. S. Evaluation of Renal Toxicity and Antifungal Activity of Free and Liposomal Amphotericin B following a Single Intravenous Dose to Diabetic Rats with Systemic Candidiasis. Antimicrob. Agents Chemother. 1996, 40, 1806-1810.
60. Koldin, M. H.; Kobayashi, G. S.; Brajtburg, J.; Medoff, G. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity to rabbits. Antimicrob. Agents Chemother. 1985, 28, 144-145.
61. Barwicz, J.; Gareau, R.; Audet, A.; Morisset, A.; Villiard, J.; Gruda I. Inhibition of the interaction between lipoproteins and amphotericin B by some delivery system. Biochem. Biophys. Res. Comm. 1991, 181, 722-728.
62. Chavanet, P.; Joly, V.; Rigaud, D.; Bolard, J.; Carbon, C.; Yeni, P. Influence of Diet on Experimental Toxicity of Amphotericin B Deoxycholate. Antimicrob. Agents Chemother. 1994, 38, 963-968.
63. Souza, L. C.; Maranhao, R. C.; Schrier, S.; Campa, A. In vitro and in vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J. Antimicrob. Agents 1993, 32, 123-132.
64. Vertut-Doi, A.; Ohnishi, O.; Bolard, J. The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrob. Agents Chemother. 1994, 38, 2373-2379.
65. Krieger, M. The use of amphotericin B to detect inhibitors of cellular cholesterol biosynthesis. Anal. Biochem. 1983, 135, 383-391.
66. Wasan, K. M.; Rosenblum, M. G.; Cheung, L.; Lopez-Berestein, G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 1994, 38, 223-227.
67. Sgoutas, D.; MacMahon, W.; Love, A.; Jerkunica, I. Interaction of cyclosporin A with human lipoproteins. J. Pharm. Pharmacol. 1986, 38, 583-588.
68. Kahan, B. D. Cyclosporine. N. Engl. J. Med. 1990, 321, 1725-1738.
69. Wiederrecht, G.; Lam, E.; Hung, S.; Martin, M.; Sigal, W. Mechanism of action of FK-506 and cyclosporin A. Ann. N.Y. Acad. Sci. 1993, 696, 9-19.
70. Borel, J. F.; Kis, Z. L. The discovery and development of cyclosporine (Sandimmune). Transplant. Proc. 1991, 23, 1867-1874.
71. Bennett, W. M. Renal effects of cyclosporine. J. Am. Acad. Dermatol. 1990, 23, 1280-1287.
72. Mayer, R. D.; Berman, S.; Cockett, A. T.; Maines, M. D. Differential effects of cyclosporin on hepatic and renal heme, cytochrome P-450 and drug metabolism. Possible role in nephrotoxicity of the drug. Biochem. Pharmacol. 1989, 38, 1001-1007.
73. Yoshimura, R.; Yoshimura, N.; Kusunose, E.; Matsui, S.; Hamashima, T.; Kishimoto, T.; Oka, T.; Kusunose, M.; Maekawa, M. Role of kidney microsomal cytochrome P-450 in cyclosporin induced nephropathy. Transplant. Proc. 1989, 21, 934-936.
74. Leunissen, K. M.; Beuman, G. H.; Bosman, F. T.; van Hoof, J. P. The nephrotoxic effects of cyclosporine metabolites. Transplant. Proc. 1988, 20, 238-239.
75. Sigal, N. H.; Dumont, F. J.; Siekierka, J. J.; Wiederrecht, G.; Parent, S. A.; Brizuela, L. Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? Transplant. Proc. 1991, 23, 2846-2849.
76. Wasan, K. M., Pritchard, P. H., Ramaswamy, M., Wong, W., Donnachie, E. M., and Brunner, L. J. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm. Res. 1997, 14 (11), 1613-1620.
77. Awni, W. N.; Kasiske, B. L.; Heim-Duthoy, K.; Vennkateswara, R. K. Long-term cyclosporine pharmacokinetic changes in renal transplant recipients. Clin. Pharmacol. Ther. 1989, 45, 41-48.
78. Awni, W. N.; Sawchuk, R. J. The pharmacokinetics of cyclosporine. II. Blood plasma binding and distribution. Drug Metab. Disp. 1985, 13, 133-138.
79. De Kippel, N.; Sennesael, J.; Lamote, J.; Ebinger, G.; De Keyser, J. Cyclosporine leukoencephalopathy induced by intravenous lipid solution. Lancet 1992, 339, 1114-1115.
80. Nemunaitis, J.; Deeg, H. J.; Yee, G. C. High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridemia. Lancet 1986, i, 744-745.
81. de Groen, P. C.; Akasmit, A. J.; Rakela, J.; Forbes, G. S.; From, R. A. F. Central nervous system toxicity after liver transplantation. N. Engl. J. Med. 1987, 377, 861-866.
82. Lemaire, M.; Tillement, J. P. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J. Pharm. Pharmacol. 1982, 34, 715-718.
83. Lemaire, M.; Pardridge, W. M.; Chaudhuri, G. Influence of blood components on the tissue uptake indices of cyclosporin in rats. J. Pharmacol. Exp. Ther. 1988, 244, 740-743.
84. Pardridge, W. M. Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J. Clin. Invest. 1979, 64, 145-154.
85. Gardier, A. M.; Mathe, D.; Guedeney, X.; Barre, J.; Benvenutti, C.; Navarro, N.; Vernillet, J.; Loisance, D.; Cachera, J. P.; Jacotot, B.; Tillement, J. P. Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther. Drug Monitoring 1993, 15, 274-280.
86. Arnadottir, M.; Thysell, H.; Nilsson-Ehle, P. Lipoprotein levels and post-heparin lipase activities in kidney transplant recipients: Ciclosporin-versus nonciclosporin-treated patients. Am. J. Kidney Dis. 1991, 17, 700-717.
87. Milton, K. A.; Edwards, G.; Ward, S. A.; Orme, M. L. E.; Breckenridge, A. M. Pharmacokinetics of halofantrine in man: Effects of food and dose size. Br. J. Clin. Pharmacol. 1989, 28, 71-77.
88. Boudreau, E. F.; Pang, L. W.; Dixon, K. E.; Webster, H. K.; Pavanand, K.; Tosingha, L.; Somutsakorn, P.; Canfield, C. J. Malaria: Treatment efficacy of halofantrine (WR 171, 699) in initial trials in Thailand. Bull. W. H. O. 1988, 66, 227-235.
89. Watkins, W. M.; Lury, J. D.; Kariuki, D.; Koech, D. K.; Oloo, J. A.; Mosoba, M.; Mjomba, M.; Gilles, H. M. Efficacy of multiple dose-halofantrine in the treatment of chloroquine resistant falciparum malaria in Kenya. Lancet 1988, ii, 247-250.
90. Pouvelle, B.; Spiegel, R.; Hsiao, L.; Howard, R. J.; Morris, R. L.; Thomas, A. P.; Taraschi, T. F. Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature 1991, 353, 73-75.
91. Grellier, P.; Rigomier, D.; Clavey, V.; Fruchart, J.; Schrevel, J. Lipid Traffic between High-Density Lipoproteins and Plasmodium falciparum-infected red blood cells. J. Cell Biol. 1991, 112, 267-277.
92. Mohanty, S.; Mishra, S. K.; Das, B. S.; Satpathy, S. K.; Mohanty, D.; Patnaik, J. K.; Bose, T. K. Altered plasma lipid pattern in falciparum malaria. Ann. Trop. Med. Parasit. 1992, 86, 601-606.
93. Maurois, P.; Pessah, M.; Eriche, I.; Alcindor, L. G. Alterations in lecithin-cholesterol acyltransferase activity during Plasmodium chabaudi rodent malaria. Biochimie 1985, 67, 227-239.
94. Vernes, A.; Dei Cas, E.; Dutoit, E.; Maurois, P.; Gentilini, J. L.; Biguet, J. Changes of serum lipoproteins during the course of human malaria. J. Pathol. Biol. 1980, 28, 457-460.
95. Cenni, B.; Meyer, J.; Brandt, R.; Betschart, B. The antimalarial drug halofantrine is bound mainly to low and high-density lipoproteins in human serum. Br. J. Clin. Pharmacol. 1995, 39, 519-526.
96. Humberstone, A. J.; Porter, C. J. H.; Edwards, G. A.; Charman, W. N. Distribution of Halofantrine between Plasma Lipoprotein fractions after IV administration to Pre- and Post-Prandial Beagle Dogs. Pharm. Res. 1995, 12 (9), S-356.
97. Scherphof, G., Van Leeuwen, B., Wilschut, J., and Damen, J. Exchange of phosphatidylcholine between small unilamellar liposomes and human plasma high-density lipoprotein involves exclusively the phospholipid in the outer monolayer of the liposome membrane. Biochim. Biophys. Acta 1983, 732, 595-599.
98. Surewicz, W. K.; Epand, R. M.; Pownall, H. J.; Hui, S. W. Human apolipoprotein AI forms thermally stable complexes with anionic but not with zwitterionic phospholipids. J. Biol. Chem. 1986, 261, 16191-16197.
99. Wasan, K. M.; Brazeau, G. A.; Keyhani, A.; Hayman, A. C.; Lopez-Berestein, G. Role of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 1993, 37, 246-250.
100. Weiss, R. B.; Sarosy, G.; Clagett-Carr, K.; Russo, M.; Leyland-Jones, B. Anthracycline analogues: The past, present, and future. Cancer Chemother. Pharmacol. 1986, 18, 185-197.
101. Arcamone, F. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture. Cancer Res. 1985, 45, 5995-5999.
102. Wasan, K. M.; Morton, R. E. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Pharm. Res. 1996, 13, 462-468.
103. Medoff, G.; Brajtburg, J.; Kobayashi G. S. Antifungal agents useful in therapy of systemic fungal infections. Annu. Rev. Pharmacol. Toxicol. 1983, 23, 303-313.
104. Mehta, R. T.; Hopfer, R. L.; Gunner, L. A.; Juliano, R. L.; Lopez-Berestein, G. Formulation, toxicity and antifungal activity in vitro of liposome-encapsulated nystatin as a therapeutic agent for systemic candidiasis. Antimicrob. Agent. Chemother. 1987, 31, 1897-1900.
105. Wasan, K. M.; Ramaswamy, M.; Cassidy, S. M.; Kazemi, M.; Strobel, F. W.; Thies, R. L. Physical Characteristics and Lipoprotein Distribution of Liposomal Nystatin in Human Plasma. Antimicrob. Agent. Chemother. 1997, 41, 1871-1875.
106. Morton, R. E.; Zilversmit, D. B. Purification and characterization of lipid transfer protein (s) from human lipoprotein-deficient plasma. J. Lipid Res. 1982, 23, 1058-1067.
107. Morton, R. E.; Zilversmit. D. B. Inter-relationships of lipid transferred by the lipid transfer protein isolated from human lipoprotein-deficient plasma. J. Biol. Chem. 1983, 258, 11751-11756.
108. Tall, A. R.; Abreau, E.; Shuman, J. Separation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein. J. Biol. Chem. 1983, 258, 2174-2178.
109. Jarnagin, A. S.; Kohr, W.; Fielding, C. Isolation and specificity of a Mr 74,000 cholesteryl ester transfer protein from human plasma. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 1854-1860.
110. Rajaram, O. V.; White, G. H.; Barter, P. J. Partial purification and characterization of a triacylglycerol-transfer protein from rabbit serum. Biochim. Biophys. Acta 1980, 617, 383-390.
111. Albers, J. J.; Tollefson, J. H.; Chen, C.-H, Steinmetz, A. Isolation and characterization of human lipid transfer proteins. Arteriosclerosis 1984, 4, 49-58.
112. Barter, P. J.; Jones, M. E. Kinetic studies of the transfer of esterified cholesterol between human plasma low and high-density lipoproteins. J. Lipid Res. 1980, 21, 238-245.
113. Ihm, J.; Ellsworth, J. L.; Chataing, B.; Harmony, J. A. K. Plasma protein-facilitated coupled exchange of phosphatidylcholine and cholesteryl ester in the absence of cholesterol esterification. J. Lipid Res. 1982, 23, 1328-1335.
114. Fielding, P. E.; Fielding, C. J. Biochemistry of Lipids, Lipoproteins and Membranes. New York; Elsvier Press: 1991.
115. Bolard, J.; Seigneuret, M.; Boudet. G. Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B. Lipid state and cholesterol content dependence. Biochim. Biophys. Acta 1980, 599, 280-293.
116. Wasan, K. M.; Ramaswamy, M.; Wong, W.,; Pritchard. P. H. Lipid Transfer Protein I facilitated transfer of cyclosporine from low-density lipoproteins to high-density lipoproteins is partially dependent on its cholesteryl ester transfer activity. J. Pharmacol. Exp. Ther. 1998, 284, 599-605.
117. Hughes, T. A.; Gaber, A. O.; Montgomery, C. E. Plasma distribution of cyclosporine within lipoproteins and "in vitro" transfer between very-low-density lipoproteins, low-density lipoproteins and high-density lipoproteins. Ther. Drug. Monit. 1991, 13, 289-295.
118. Wasan, K. M.; Ramaswamy, M.; McIntosh, M. P.; Porter, C. J. H.; Charman, W. N. Differences in lipoprotein concentration and lipid transfer protein I activity modify the in vitro plasma distribution of halofan trine in dyslipidemic plasma. Pharm. Res. 1997, 14 (11), S-277.
119. Wasan, K. M.; Grossie, V. B., Jr.; Lopez-Berestein, G. Concentrations in serum and tissue distribution of free and liposomal amphotericin B in rats on continuous Intralipid infusion. Antimicrob. Agents Chemother. 1994, 38, 2224-2226.
120. Wong, W.; Ramaswamy, M.; Pritchard, H. P.; Brunner, L. J.; Wasan, K. M. The Influence of total plasma and lipoprotein lipid and protein concentrations on the binding of cyclosporine to lipoproteins. Pharm. Res. 1997, 14 (11), S-284.
121. Feingold, K. R.; Krauss, R. M.; Pang, M.; Doerrler, W.; Jensen, P.; Grunfeld, C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low-density lipoprotein subclass pattern. J. Clin. Endocrinology Metab. 1993, 76, 1423-1431.
122. Grunfeld, C.; Pang. M.; Doerrler, W.; Shigenaga, J. K.; Jensen, P.; Feingold, K. R. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 1992, 74, 2045-2051.
123. Umeki, S Decreases in serum cholesterol levels in advanced lung cancer. Respiration 1993, 60, 178-181.
124. Vitols, S.; Gahrton, G.; Bjorkholm, M.; Peterson, C. Hypocholesterolemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumor cells: Evidence from studies in patients with leukemia. Lancet 1985, iv, 1150-1154.
125. Highley, M. S.; De Bruijn, E. A. Erythrocytes and the Transport of Drugs and Endogenous Compounds. Pharm. Res. 1996, 13, 186-195.
126. Cushley, P. J.; Treleaven, W. D.; Pramar, Y. I.; Ghana, R. S.; Fenske, D. B. Surface diffusion in human serum lipoproteins. Biochem. Biophys. Res. Com. 1987, 146, 1139-1145.